Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase

HAYWARD, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) — Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy …

Continue

Do you trust this headline?

Based on recent headline ratings, 84% of this readership currently trusts the local media, which has an average score of 83% regionally and is currently trending positive.

84%

Media Trust Score

Read All

In

News